Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
NGF Treatment for Patients With Neuropathic Corneal Pain
NCT05700864 · Tufts Medical Center · PHASE1 · withdrawn · last registry update 2023-01-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding of study was withdrawn” | – | Registry record, Tufts Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NTRK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-23Also stopped (withdrawn): OHSU Knight Cancer Institute, Alectinib + Alpelisib (NCT05238831)
- 2024-01-10Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A1811 + TAS-102, Regorafenib , Fruquintinib (NCT06199973)
- 2024-01-05Results posted on the registry: The University of Texas Health Science Center at San Antonio, Vorinostat + Hydroxychloroquine (NCT02316340)
- 2023-11-22Results posted on the registry: Arkadiusz Z. Dudek, MD, PAC-1 + Entrectinib (NCT04589832)
- 2023-11-22Also stopped (terminated): Arkadiusz Z. Dudek, MD, PAC-1 + Entrectinib (NCT04589832)
- 2023-11-20Phase 3 first posted: Bristol-Myers Squibb, Repotrectinib + Crizotinib (NCT06140836)
- 2023-11-15Results posted on the registry: Dana-Farber Cancer Institute, Regorafenib (NCT02657551)
- 2023-11-15Results posted on the registry: Dana-Farber Cancer Institute, Topical Tazarotene (NCT04071756)
- 2023-11-09Results posted on the registry: Abramson Cancer Center at Penn Medicine, hydroxychloroquine + entinostat (NCT03215264)
- 2023-11-07Results posted on the registry: Sarcoma Alliance for Research through Collaboration, Regorafenib + Placebo (NCT02048371)
- 2023-11-07Results posted on the registry: Hoffmann-La Roche, Regorafenib + Atezolizumab (NCT03555149)
- 2023-11-07Also stopped (terminated): Hoffmann-La Roche, Regorafenib + Atezolizumab (NCT03555149)
- 2023-10-23Also stopped (terminated): Case Comprehensive Cancer Center, Regorafenib + Gemcitabine Hydrochloride (NCT02383433)
- 2023-10-16Also stopped (terminated): UNICANCER, Regorafenib and Irinotecan + Irinotecan (NCT03722108)
- 2023-09-26Also stopped (withdrawn): Turning Point Therapeutics, Inc., repotrectinib (TPX-0005) (NCT05828277)
- 2023-09-15Results posted on the registry: SCRI Development Innovations, LLC, Afatinib + Regorafenib (NCT02795156)
- 2023-08-07Results posted on the registry: Hoffmann-La Roche, Alectinib (NCT04644315)
- 2023-08-07Also stopped (terminated): Hoffmann-La Roche, Alectinib (NCT04644315)
- 2023-08-01Results posted on the registry: Stanford University, Methotrexate + Regorafenib (NCT03520842)
- 2023-06-23Results posted on the registry: Dompé Farmaceutici S.p.A, cenegermin-bkbj (NCT04485546)
- 2023-06-07Also stopped (withdrawn): Translational Research in Oncology, Regorafenib in combination with Tislelizumab (NCT05582031)
- 2023-05-30Results posted on the registry: Bayer, Pembrolizumab + Regorafenib (Stivarga, BAY73-4506) (NCT04696055)
- 2023-05-17Phase 3 first posted: Hoffmann-La Roche, Ipatasertib + Tiragolumab (NCT05862285)
- 2023-04-03Phase 3 first posted: Sun Yat-sen University, Regorafenib and DIBIRI + Regorafenib (NCT05794971)
- 2023-03-15Phase 3 first posted: Cancer Research UK, Entrectinib (NCT05770544)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision